Alamar Biosciences has partnered with leading U.S. universities to launch a nationwide proteomics study analyzing around 21,000 plasma samples from 10,000 Alzheimer's and related dementia patients. Using its NULISAseq™ Neuro 220 test kit, the project aims to accelerate discovery and validation of blood-based biomarkers for neurodegenerative diseases. Data generated will be openly accessible through the National Alzheimer’s Coordinating Center, supporting AI-driven research and a national data competition. This initiative could significantly enhance understanding of disease mechanisms and improve diagnosis and treatment development.
Institutional investors are favoring spot Bitcoin and Ethereum ETFs like BlackRock IBIT and Fidelity FBTC, driving steady inflows that support Bitcoin's price around $64,119 and Ethereum near $1,897. This trend highlights a preference for lower-fee, ...
The Monad Foundation's $60 million liquidity program, aimed at reducing selling pressure by allowing early investors to sell locked MON tokens at a discount, was largely rejected as most investors chose to hold their tokens. While this could suggest ...
Zcash (ZEC) has unexpectedly broken out of its recent consolidation, driven by a bullish golden EMA crossover around $495 while trading near $509. This technical signal suggests increased intermediate momentum, supported by strong long-term support l...
Long-term U.S. Treasury yields surged to their highest levels in over two decades due to ongoing tensions between the U.S. and Iran, with the 30-year yield nearing 5.322% and the 10-year yield at 4.736%. Rising geopolitical risks, including Iran's re...
World Liberty Financial (WLFI), backed by the Trump family, is financially supporting WorldClaw, a Hong Kong AI platform using Chinese AI models flagged by the US Pentagon for military ties. WLFI's USD1 stablecoin is used for payments on WorldClaw, c...
